Market open
VYNE Therapeutics Inc./$VYNE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Ticker
$VYNE
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
13
ISIN
US92941V3087
Website
VYNE Metrics
BasicAdvanced
$19M
-
-$0.99
-
-
Price and volume
Market cap
$19M
52-week high
$2.60
52-week low
$1.27
Average daily volume
206K
Financial strength
Current ratio
4.468
Quick ratio
4.09
Total debt to equity
0.143
Management effectiveness
Return on assets (TTM)
-38.36%
Return on equity (TTM)
-66.15%
Valuation
Price to revenue (TTM)
91.569
Price to book
0.47
Price to tangible book (TTM)
0.47
Growth
Revenue change (TTM)
43.03%
Earnings per share change (TTM)
-31.92%
3-year revenue growth (CAGR)
-11.71%
3-year earnings per share growth (CAGR)
-60.70%
VYNE News
AllArticlesVideos
FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold
Benzinga·2 weeks ago
VYNE Therapeutics Provides Update on VYN202 Program
GlobeNewsWire·2 weeks ago
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for VYNE Therapeutics Inc. stock?
VYNE Therapeutics Inc. (VYNE) has a market cap of $19M as of May 09, 2025.
What is the P/E ratio for VYNE Therapeutics Inc. stock?
The price to earnings (P/E) ratio for VYNE Therapeutics Inc. (VYNE) stock is 0 as of May 09, 2025.
Does VYNE Therapeutics Inc. stock pay dividends?
No, VYNE Therapeutics Inc. (VYNE) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next VYNE Therapeutics Inc. dividend payment date?
VYNE Therapeutics Inc. (VYNE) stock does not pay dividends to its shareholders.
What is the beta indicator for VYNE Therapeutics Inc.?
VYNE Therapeutics Inc. (VYNE) does not currently have a Beta indicator.